GE Healthcare recalled 2,306 Carescape Central Station devices on September 5, 2025, due to a software issue. The problem can cause a continuous reboot cycle, risking loss of patient monitoring. The recall affects devices with software version V3.0.5 when connected in specific network conditions.
GE HealthCare has identified an issue affecting Carescape" Central Station (CSCS) with software version V3.0.5, which can cause the system to enter a continuous reboot cycle. If this occurs, a loss of central monitoring of connected patients could result. This issue occurs only when the number of central stations connected to the network is 118, 119 or 120.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Wipro GE Healthcare Private Ltd. or your healthcare provider for instructions. Notification method: Letter
The recall involves the GE Healthcare Carescape Central Station (CSCS) V3 MAS800 Desktop with software version V3.0.5, Part Number 5867474-03. These units were distributed worldwide.
A continuous reboot cycle may occur when 118 to 120 central stations connect to the network. This can lead to a loss of central monitoring of patients, posing a significant risk in healthcare settings.
No specific incidents or injuries have been reported. Nonetheless, the risk of losing patient monitoring is significant.
Stop using the Carescape Central Station immediately. Follow the manufacturer’s instructions for the recall and contact Wipro GE Healthcare Private Ltd. or your healthcare provider for further actions.
For assistance, call Wipro GE Healthcare Private Ltd. or visit their website. More details are available at the FDA recall notice.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.